应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。
关闭
CAR 安飞士
未开盘 01-13 16:00:00 EST
125.18
-1.94
-1.53%
盘后
125.18
+0.00
0.00%
18:52 EST
最高
128.00
最低
124.51
成交量
34.97万
今开
127.91
昨收
127.12
日振幅
2.75%
总市值
44.06亿
流通市值
18.49亿
总股本
3,520万
成交额
4,388万
换手率
2.37%
流通股本
1,477万
市净率
--
ROE
--
每股收益
0.00
52周最高
--
52周最低
--
市盈率
--
股息
--
股息收益率
--
ROA
--
分时
五日
日K
周K
月K
数据加载中...
北京优虎网络科技有限公司
资讯
新帖
简况
WiseTech、REA与CAR集团被视为最能抵御AI威胁的澳大利亚科技媒体股——市场快评
投资观察 · 01-07
WiseTech、REA与CAR集团被视为最能抵御AI威胁的澳大利亚科技媒体股——市场快评
2025 ASH | 强生公布 CD19/CD20 双靶点 CAR-T 1b 期最新临床进展与生物标志物分析！
医麦客 · 2025-12-24
2025 ASH | 强生公布 CD19/CD20 双靶点 CAR-T 1b 期最新临床进展与生物标志物分析！
近半新增药品为一类新药！2025国谈结果公布：五款CAR-T均商保破冰 ，创新药支付迈入“价值时代”
智通财经网 · 2025-12-07
近半新增药品为一类新药！2025国谈结果公布：五款CAR-T均商保破冰 ，创新药支付迈入“价值时代”
五款CAR-T产品纳入2025年商保创新药目录
北京商报 · 2025-12-07
五款CAR-T产品纳入2025年商保创新药目录
“抗癌神药”屡登热搜，CAR-T如何从绝症救星走向百万患者？
21世纪经济报道 · 2025-12-04
“抗癌神药”屡登热搜，CAR-T如何从绝症救星走向百万患者？
石药HER2单抗报产，华润三九拿下罕见病创新药，国产CAR-T超8.6亿美元出海
医药经济报 · 2025-11-11
石药HER2单抗报产，华润三九拿下罕见病创新药，国产CAR-T超8.6亿美元出海
改写“进口依赖”！进博会医疗展区直击：十万转离心机破壁、伽玛刀“中国造”、CAR-T疗法可及｜聚焦2025进博会
华夏时报网 · 2025-11-10
改写“进口依赖”！进博会医疗展区直击：十万转离心机破壁、伽玛刀“中国造”、CAR-T疗法可及｜聚焦2025进博会
又一款国产CAR-T上市；上海满13周岁女孩免费接种HPV
21世纪经济报道 · 2025-11-10
又一款国产CAR-T上市；上海满13周岁女孩免费接种HPV
诺纳生物扩大与Umoja合作 共同推进体内CAR-T细胞疗法研发
金吾财讯 · 2025-11-05
诺纳生物扩大与Umoja合作 共同推进体内CAR-T细胞疗法研发
Caribou Biosciences报告了关于同种异体CAR T疗法的临床数据，而Kyverna Therapeutics则推进了自身免疫项目Caribou Biosciences Reports Clinical Data on Allogeneic CAR T Therapies While Kyverna Therapeutics Advances Autoimmune Program
动脉网 · 2025-11-05
Caribou Biosciences报告了关于同种异体CAR T疗法的临床数据，而Kyverna Therapeutics则推进了自身免疫项目Caribou Biosciences Reports Clinical Data on Allogeneic CAR T Therapies While Kyverna Therapeutics Advances Autoimmune Program
微滔生物完成超亿元规模天使轮融资，启明创投领投
新浪科技 · 2025-11-05
微滔生物完成超亿元规模天使轮融资，启明创投领投
国谈收官：CAR-T实现突破，首版商保目录能否打开支付新局？
21世纪经济报道 · 2025-11-04
国谈收官：CAR-T实现突破，首版商保目录能否打开支付新局？
CAR-T药物有望进入商保；绿谷医药违规推广被罚｜医药早参
每日经济新闻 · 2025-11-03
CAR-T药物有望进入商保；绿谷医药违规推广被罚｜医药早参
异动解读 | 安飞士租车股价盘中大跌5.02%，多家券商下调目标价
异动解读 · 2025-10-29
异动解读 | 安飞士租车股价盘中大跌5.02%，多家券商下调目标价
异动解读 | 安飞士股价盘中大跌6.71%，因预计年度营收下滑
异动解读 · 2025-10-29
异动解读 | 安飞士股价盘中大跌6.71%，因预计年度营收下滑
Avis Budget考虑提价以改善收入
投资观察 · 2025-10-29
Avis Budget考虑提价以改善收入
安飞士第三季度业绩超预期，国际业务表现更为强劲
老虎资讯综合 · 2025-10-28
安飞士第三季度业绩超预期，国际业务表现更为强劲
再生元终止开发一款双靶点CAR-T；葛兰素史克BCMA ADC药物Blenrep获批上市
氨基观察 · 2025-10-24
再生元终止开发一款双靶点CAR-T；葛兰素史克BCMA ADC药物Blenrep获批上市
【券商聚焦】建银国际：预计第三季度中国银行业利润增速将回升
金吾财讯 · 2025-10-21
【券商聚焦】建银国际：预计第三季度中国银行业利润增速将回升
两天4家上市药企官宣BD交易，两笔潜在最高金额超过15亿美元
澎湃新闻 · 2025-10-17
两天4家上市药企官宣BD交易，两笔潜在最高金额超过15亿美元
加载更多
公司概况
公司名称：
安飞士
所属市场：
NASDAQ
上市日期：
--
主营业务：
Avis Budget Group, Inc.是一家全球领先的车辆租赁和汽车共享服务提供商，通过Avis、Budget和Zipcar运营着业内最受认可的三个品牌。该公司是北美、欧洲、澳大利亚、新西兰和某些地区领先的车辆租赁运营商。
发行价格：
--
{"stockData":{"symbol":"CAR","market":"US","secType":"STK","nameCN":"安飞士","latestPrice":125.18,"timestamp":1768338000000,"preClose":127.12,"halted":0,"volume":349682,"hourTrading":{"tag":"盘后","latestPrice":125.18,"preClose":125.18,"latestTime":"18:52 EST","volume":21204,"amount":2654313.36,"timestamp":1768348359046},"delay":0,"changeRate":-0.015261170547514141,"floatShares":14770456,"shares":35196992,"eps":-59.65909,"marketStatus":"未开盘","change":-1.94,"latestTime":"01-13 16:00:00 EST","open":127.91,"high":128,"low":124.51,"amount":43878247.72326,"amplitude":0.027454,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-59.65909,"tradingStatus":0,"nextMarketStatus":{"tag":"盘前交易","tradingStatus":1,"beginTime":1768381200000},"marketStatusCode":0,"adr":0,"adrRate":0,"exchange":"NASDAQ","adjPreClose":127.12,"postHourTrading":{"tag":"盘后","latestPrice":125.18,"preClose":125.18,"latestTime":"18:52 EST","volume":21204,"amount":2654313.36,"timestamp":1768348359046},"volumeRatio":0.6174323582095075,"optionData":{"bulkOrders":[{"symbol":"CAR","call":false,"expireDate":1768539600000,"strike":"185.0","timestamp":1768336873622,"price":59.36,"volume":6260,"amount":37159360,"type":"+"},{"symbol":"CAR","call":false,"expireDate":1768539600000,"strike":"185.0","timestamp":1768335147302,"price":57.81,"volume":3120,"amount":18036720,"type":"-"}]},"impliedVol":0.5897,"impliedVolPercentile":0.576},"requestUrl":"/m/hq/s/CAR","defaultTab":"news","newsList":[{"id":"1195653498","title":"WiseTech、REA与CAR集团被视为最能抵御AI威胁的澳大利亚科技媒体股——市场快评","url":"https://stock-news.laohu8.com/highlight/detail?id=1195653498","media":"投资观察","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1195653498?lang=zh_cn&edition=full","pubTime":"2026-01-07 06:54","pubTimestamp":1767740072,"startTime":"0","endTime":"0","summary":"杰富瑞分析师罗杰·塞缪尔指出，在澳大利亚科技与媒体板块中，WiseTech Global、REA集团与CAR集团最具备抵御人工智能竞争威胁的能力。塞缪尔分析认为，软件开发企业WiseTech受到其所在物流行业复杂性的天然壁垒保护。他在研究报告中强调，由新闻集团控股的房地产广告平台REA拥有坚固的数据护城河、强大的品牌影响力以及房产经纪人的高度忠诚度。对于CAR集团，他认为任何试图通过AI技术挑战其地位的汽车广告平台都必须提供更卓越的用户体验，而这一领域正是该龙头企业持续创新的核心战场。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK7002","REA.AU","WTC.AU","BK7503","CAR","CAR.AU","BK4022","BK4230","BK7016"],"gpt_icon":0},{"id":"2593720654","title":"2025 ASH | 强生公布 CD19/CD20 双靶点 CAR-T 1b 期最新临床进展与生物标志物分析！","url":"https://stock-news.laohu8.com/highlight/detail?id=2593720654","media":"医麦客","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2593720654?lang=zh_cn&edition=full","pubTime":"2025-12-24 07:20","pubTimestamp":1766532031,"startTime":"0","endTime":"0","summary":"2025 年 12 月 24 日医麦客新闻 eMedClub News本月 9 日，强生在第 65 届美国血液学会年会上以口头报告形式，更新了其双靶点 CAR-T 疗法 Prizlo-cel的 1b 期临床试验数据及生物标志物关联分析。目前也仅有约 40% 的患者通过现有的单抗原靶向 CD19 CAR-T 细胞疗法获得长期缓解。ORR 达 91%，CR 率 75% 该数据显著优于传统 CD19 CAR-T 历史数据。Grade 3 中位数略高，但 Grade 1 和 Grade 2 中同样有高峰值浓度样本，并未显示 ICANS 严重程度与 CAR-T 细胞扩增有显著关联。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251224072631a470912f&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251224072631a470912f&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LU2505996681.GBP","IE00BFTCPJ56.SGD","IE00BGHQF631.EUR","IE00B4R5TH58.HKD","LU0345769128.USD","LU1023059063.AUD","IE00BJT1NW94.SGD","BK4559","LU1162221912.USD","CAR","IE00B19Z3581.USD","LU1778281490.HKD","IE00B7SZLL34.SGD","LU1732799900.SGD","LU0289739699.SGD","LU0070217475.USD","LU1196500208.SGD","LU2750360641.GBP","BK4504","LU0787776722.HKD","LU2129689431.USD","LU0466842654.USD","LU1244550577.SGD","LU2505996509.AUD","IE00B42XCP33.USD","JNJ","ASH","BK4022","LU2750360997.AUD","BK4592","LU0114720955.EUR","LU0234570918.USD","LU0234572021.USD","LU1059921491.USD","SG9999002224.SGD","LU1032955483.USD","IE00BFXG1179.USD","LU2430703095.HKD","LU1280957306.USD","LU2468319806.SGD","LU0203347892.USD","LU2463526074.USD","LU1057294990.SGD","LU0795875086.SGD","IE0034235303.USD","LU1496350502.SGD","LU2112291526.USD","BK4534","IE00BZ1G4Q59.USD","IE00B1BXHZ80.USD"],"gpt_icon":0},{"id":"2589879103","title":"近半新增药品为一类新药！2025国谈结果公布：五款CAR-T均商保破冰 ，创新药支付迈入“价值时代”","url":"https://stock-news.laohu8.com/highlight/detail?id=2589879103","media":"智通财经网","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2589879103?lang=zh_cn&edition=full","pubTime":"2025-12-07 16:08","pubTimestamp":1765094886,"startTime":"0","endTime":"0","summary":"今日上午，在广州白云区举行的2025创新药高质量发展大会上，万众瞩目的年度医保准入大考——2025国谈结果正式揭晓。","market":"fut","thumbnail":"https://img.zhitongcaijing.com/image/20251207/20251207161234_79991.png?x-oss-process=image/format,jpg/quality,q_60","type":0,"news_type":0,"thumbnails":["https://img.zhitongcaijing.com/image/20251207/20251207161234_79991.png?x-oss-process=image/format,jpg/quality,q_60"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1378479.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"highlight_zhitongcaijin","symbols":["06978","CAR","BK1574","BK4022","BK1161","159992","BK4230"],"gpt_icon":0},{"id":"2589875563","title":"五款CAR-T产品纳入2025年商保创新药目录","url":"https://stock-news.laohu8.com/highlight/detail?id=2589875563","media":"北京商报","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2589875563?lang=zh_cn&edition=full","pubTime":"2025-12-07 13:19","pubTimestamp":1765084748,"startTime":"0","endTime":"0","summary":"北京商报讯12月7日，《商业健康保险创新药品目录（2025年）》正式发布，18家创新药企业的19款药品成功纳入，其中包括五款CAR-T产品。具体来看，包括复星凯瑞的阿基仑赛注射液、药明巨诺的瑞基奥仑赛注射液、驯鹿生物的伊基奥仑赛注射液、合源生物的纳基奥仑赛注射液、以及恺兴生命科技的泽沃基奥仑赛注射液。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202512073584556645.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202512073584556645.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["06978","CAR","159992","BK4230","BK1574","BK4022","BK1161"],"gpt_icon":0},{"id":"2588009570","title":"“抗癌神药”屡登热搜，CAR-T如何从绝症救星走向百万患者？","url":"https://stock-news.laohu8.com/highlight/detail?id=2588009570","media":"21世纪经济报道","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2588009570?lang=zh_cn&edition=full","pubTime":"2025-12-04 17:29","pubTimestamp":1764840543,"startTime":"0","endTime":"0","summary":"一家医院血液科诊室内，医生正与一位白血病患者家属低声讨论着治疗可能性，当提到“CAR-T”时，家属眼中刚刚燃起的希望很快又被沉重取代——他们刚刚询问了价格。国内已上市的CAR-T疗法价格普遍在百万元左右。当有人惊叹于“一针清零癌细胞”的神奇疗效时，更多人面对的是它百万级的价格门槛。近期，价格高达百万的“抗癌针”屡屡登上热搜榜单。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202512043582753914.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202512043582753914.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["CAR","BK4022","BK4230"],"gpt_icon":0},{"id":"2582365624","title":"石药HER2单抗报产，华润三九拿下罕见病创新药，国产CAR-T超8.6亿美元出海","url":"https://stock-news.laohu8.com/highlight/detail?id=2582365624","media":"医药经济报","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2582365624?lang=zh_cn&edition=full","pubTime":"2025-11-11 19:07","pubTimestamp":1762859220,"startTime":"0","endTime":"0","summary":"石药集团帕妥珠单抗上市申请获受理11月11日，CDE官网显示，石药集团递交的帕妥珠单抗注射液上市申请获受理，用于治疗HER2阳性乳腺癌。帕妥珠单抗2012年首次获美国FDA批准上市，2018年首次在中国获批上市。虽然受到生物类似药冲击，但罗氏的帕妥珠单抗在2024年的全球销售额仍高达40.97亿美元。目前，LYL273已获得美国FDA授予的mCRC快速通道指定。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/relnews/hk/2025-11-11/doc-infwzvxy5623725.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["IE0008368742.USD","LU1807302812.USD","LU2039709279.SGD","BK0183","LU1226287792.SGD","BK1515","000999","BK0060","IE00BZ08YS42.EUR","LU0067412154.USD","LU0326950275.SGD","LU1008478684.HKD","LU1152091754.HKD","IE00B031HY20.USD","BK0012","LU0880133367.SGD","BK1574","LU1226288170.HKD","06978","LU1993786604.SGD","LU1226287875.USD","BK1161","BK4230","LU1328277881.USD","IE0008369823.USD","IE00B543WZ88.USD","LU1226288253.USD","BK0239","BK0175","BK0196","CAR","BK0028","LU0140636845.USD","BK0185","LU0072913022.USD","01093","159992","IE00BZ08YR35.GBP","BK1521","BK0188","LU1813983027.USD","LU1152091168.USD","LU0501845795.SGD","BK1191","LU1226287529.USD","IE00BZ08YT58.USD","LU1960683339.HKD","LU1951186391.HKD","IE00B5MMRT66.SGD","LU0314109678.HKD"],"gpt_icon":0},{"id":"2582262008","title":"改写“进口依赖”！进博会医疗展区直击：十万转离心机破壁、伽玛刀“中国造”、CAR-T疗法可及｜聚焦2025进博会","url":"https://stock-news.laohu8.com/highlight/detail?id=2582262008","media":"华夏时报网","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2582262008?lang=zh_cn&edition=full","pubTime":"2025-11-10 17:04","pubTimestamp":1762765456,"startTime":"0","endTime":"0","summary":"2025年11月5日至10日，中国国际进口博览会（下称“进博会”）在上海如期举行，在1.1馆的医疗器械展馆，《华夏时报》记者仿佛步入一场关乎人类健康的未来图景——海尔生物以数智化方案破解实验室痛点，医科达实现全线产品“中国造”，复星医药则让医疗科技从“治愈”走向“生活”。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202511103559856257.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202511103559856257.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["CAR","BK4022","BK4230"],"gpt_icon":0},{"id":"2582681142","title":"又一款国产CAR-T上市；上海满13周岁女孩免费接种HPV","url":"https://stock-news.laohu8.com/highlight/detail?id=2582681142","media":"21世纪经济报道","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2582681142?lang=zh_cn&edition=full","pubTime":"2025-11-10 08:06","pubTimestamp":1762733164,"startTime":"0","endTime":"0","summary":"政策动向上海：本市满13周岁女孩可免费接种人乳头瘤病毒（HPV）疫苗11月9日，据上海发布官微消息，上海市卫健委介绍，自2025年11月10日起，我国将在现行国家免疫规划疫苗基础上，将人乳头瘤病毒（HPV）疫苗纳入国家免疫规划，组织各地为2011年11月10日以后出生的满13周岁女孩，免费接种2剂次双价HPV疫苗（间隔6个月）。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202511103559111386.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202511103559111386.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["CAR","BK4230","BK4022"],"gpt_icon":0},{"id":"2581787771","title":"诺纳生物扩大与Umoja合作 共同推进体内CAR-T细胞疗法研发","url":"https://stock-news.laohu8.com/highlight/detail?id=2581787771","media":"金吾财讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2581787771?lang=zh_cn&edition=full","pubTime":"2025-11-05 23:34","pubTimestamp":1762356856,"startTime":"0","endTime":"0","summary":"金吾财讯 | 诺纳生物宣布与Umoja Biopharma11月5日达成一项评估与许可协议。双方计划将诺纳生物的HCAb Harbour Mice平台和NonaCarFxTM平台与Umoja的VivoVecTM平台相结合，共同推进多款体内CAR-T细胞疗法研发。根据协议条款，诺纳生物将有权获得首付款、潜在选择权付款，以及合作项目相关里程碑付款。Umoja将负责所有后续产品的开发和商业化工作。","market":"other","thumbnail":"https://static.szfiu.com/news/20210810/NTA4OTM0NjA2MTc=.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20210810/NTA4OTM0NjA2MTc=.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"294159","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CAR","BK4230","BK4022"],"gpt_icon":0},{"id":"2581779056","title":"Caribou Biosciences报告了关于同种异体CAR T疗法的临床数据，而Kyverna Therapeutics则推进了自身免疫项目Caribou Biosciences Reports Clinical Data on Allogeneic CAR T Therapies While Kyverna Therapeutics Advances Autoimmune Program","url":"https://stock-news.laohu8.com/highlight/detail?id=2581779056","media":"动脉网","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2581779056?lang=zh_cn&edition=full","pubTime":"2025-11-05 16:03","pubTimestamp":1762329780,"startTime":"0","endTime":"0","summary":"Caribou presented findings from trials involving its allogeneic CAR T therapies, which use donor-derived cells rather than a patient’s own cells. These therapies were tested in two separate cancer indications, though specific details regarding efficacy or safety outcomes were not disclosed in the report.Caribou公布了其同种异体CAR T疗法的试验结果，该疗法使用捐赠者来源的细胞而非患者自身的细胞。Meanwhile, Kyverna announced plans to move forward with its CAR T program aimed at treating autoimmune conditions. This marks a shift from the traditional focus of CAR T therapy on oncology and represents an effort to expand the technology’s applications into other therapeutic areas. Both companies continue to explore innovative approaches within this rapidly evolving sector of biotechnology..同时，Kyverna 宣布计划推进其旨在治疗自身免疫性疾病的 CAR T 项目。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025110516052697554e2c&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025110516052697554e2c&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["CAR","LENZ","BK4230","CRBU","BK4139","BK4007","KYTX","BK4022","BK4539"],"gpt_icon":0},{"id":"2581909777","title":"微滔生物完成超亿元规模天使轮融资，启明创投领投","url":"https://stock-news.laohu8.com/highlight/detail?id=2581909777","media":"新浪科技","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2581909777?lang=zh_cn&edition=full","pubTime":"2025-11-05 09:55","pubTimestamp":1762307700,"startTime":"0","endTime":"0","summary":"新浪科技讯 11月5日上午消息，近日，全球体内细胞治疗领域的创新企业，微滔生物科技 有限公司，宣布完成超亿元人民币规模的天使轮融资。本轮融资由启明创投领投，B Capital、杏泽资本及顺禧基金共同跟投，融资资金将主要用于核心技术平台迭代优化以及首款候选产品在自身免疫疾病领域的临床转化和开发。 微滔生物成立于2025年6月25日，系北京沙砾生物医药股份有限公司的in vivo CAR-T平台分拆而成。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/tech/shenji/2025-11-05/doc-infwifvz4517274.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["CAR","BK4022","BK4230"],"gpt_icon":0},{"id":"2580141738","title":"国谈收官：CAR-T实现突破，首版商保目录能否打开支付新局？","url":"https://stock-news.laohu8.com/highlight/detail?id=2580141738","media":"21世纪经济报道","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2580141738?lang=zh_cn&edition=full","pubTime":"2025-11-04 19:33","pubTimestamp":1762256018,"startTime":"0","endTime":"0","summary":"2025年10月30日至11月3日，国家基本医保目录谈判与商保创新药目录价格协商在北京全国人大会议中心举行，为期五天，成为国家医保局成立以来，8次医保谈判中历时最久的一次。与以往最大的不同在于，此次首次将商业健康保险创新药目录（简称“商保创新药目录”）纳入政策框架，成为扩大创新药保障范围，构建创新药多元支付体系的关键举措。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202511043554824564.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202511043554824564.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["CAR","BK4022","BK4230"],"gpt_icon":0},{"id":"2580232946","title":"CAR-T药物有望进入商保；绿谷医药违规推广被罚｜医药早参","url":"https://stock-news.laohu8.com/highlight/detail?id=2580232946","media":"每日经济新闻","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2580232946?lang=zh_cn&edition=full","pubTime":"2025-11-03 07:20","pubTimestamp":1762125650,"startTime":"0","endTime":"0","summary":"NO.1药明巨诺CAR-T药物有望进入商保目录据媒体报道，药明巨诺的CAR-T细胞药物瑞基奥仑赛注射液在协商进入商保（商业健康保险）创新药目录方面进展顺利，有望纳入该目录。这是国内获批上市的第一个国产1类CAR-T，上市后的定价是129万元/针。点评：商保目录的突破，标志着我国多层次医疗保障体系正加速构建，通过“商保+创新药”模式缓解基本医保压力，为更多高价疗法打通可及性路径。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202511033552828620.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202511033552828620.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["CAR","BK1515","BK4230","BK4022","BK1161","09939","BK1574"],"gpt_icon":0},{"id":"1155887050","title":"异动解读 | 安飞士租车股价盘中大跌5.02%，多家券商下调目标价","url":"https://stock-news.laohu8.com/highlight/detail?id=1155887050","media":"异动解读","labels":["movement"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1155887050?lang=zh_cn&edition=full","pubTime":"2025-10-29 22:47","pubTimestamp":1761749254,"startTime":"0","endTime":"0","summary":"周三盘中，租车巨头安飞士股价大跌5.02%，引发市场关注。这一跌势似乎与多家华尔街投行下调公司目标股价有关。据悉，杰富瑞证券将安飞士的目标价从200美元大幅下调至175美元。这些知名投行的一致行动，可能反映了分析师对安飞士未来业绩前景的担忧。安飞士作为全球领先的租车公司之一，其股价走势往往被视为旅游业和消费者信心的晴雨表。此次股价大跌和目标价下调可能会引发投资者对整个行业前景的重新评估。","market":"nz","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_cn","symbols":["CAR"],"gpt_icon":0},{"id":"1151994892","title":"异动解读 | 安飞士股价盘中大跌6.71%，因预计年度营收下滑","url":"https://stock-news.laohu8.com/highlight/detail?id=1151994892","media":"异动解读","labels":["movement"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1151994892?lang=zh_cn&edition=full","pubTime":"2025-10-29 03:04","pubTimestamp":1761678281,"startTime":"0","endTime":"0","summary":"10月28日周二，租车巨头安飞士集团（Avis Budget Group，股票代码：CAR）股价在盘中大幅下挫，跌幅高达6.71%，引发投资者广泛关注。\n\n据悉，安飞士股价大跌的主要原因是公司发布了令市场失望的财务预期。公司预计其年度营业收入将出现下降，这一消息立即引发了投资者的担忧，导致股价应声下跌。\n\n作为全球知名的租车服务提供商，安飞士的业绩预警可能反映出更广泛的经济环境变化或行业挑战。分析人士指出，这可能与旅游业复苏放缓、消费者支出谨慎或商务旅行需求变化有关。投资者将密切关注公司未来的财报和业绩指引，以评估其长期增长前景。","market":"sg","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_cn","symbols":["CAR"],"gpt_icon":0},{"id":"1172190736","title":"Avis Budget考虑提价以改善收入","url":"https://stock-news.laohu8.com/highlight/detail?id=1172190736","media":"投资观察","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1172190736?lang=zh_cn&edition=full","pubTime":"2025-10-29 02:14","pubTimestamp":1761675290,"startTime":"0","endTime":"0","summary":"1410 ET - 安飞士集团正在寻求提价，以帮助提升每日收入。由于汽车租赁价格未能跟上通货膨胀，美国第三季度的每辆车收入（RPD）下降了3%，高管在分析师电话会议上解释道。“我对此并不满意，”CEO布莱恩·蔡（Brian Choi）表示。为了合理化提价，蔡希望改善安飞士的客户体验，以将其与其他汽车租赁公司区分开来。他表示：“你需要给客户提供更多一些的东西。”蔡认为，在汽车租赁行业，客户体验的标准已经相当低，因此仍有很大的改进空间。安飞士集团股价目前下跌5.8%，但年初至今上涨了81%。（katherine.hamilton@wsj.com）","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4230","BK4022","CAR"],"gpt_icon":0},{"id":"1180659367","title":"安飞士第三季度业绩超预期，国际业务表现更为强劲","url":"https://stock-news.laohu8.com/highlight/detail?id=1180659367","media":"老虎资讯综合","labels":["dataReport","movement","express"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1180659367?lang=zh_cn&edition=full","pubTime":"2025-10-28 06:00","pubTimestamp":1761602416,"startTime":"0","endTime":"0","summary":"10月28日，$安飞士$公布的第三季度财报显著超出分析师预期，使该租车公司盘后股价一度飙升逾12%，投资者对其强劲表现表示欢迎。公司第三季度调整后每股收益为$10.11，轻松超过分析师预估的$8.24，高出$1.87。在美洲地区，调整后EBITDA达到$3.98亿，相比去年同期的$3.84亿有所增长，这主要得益于较低的车队成本和租赁天数增加1%，部分被每日收入下降1%所抵消。国际业务表现更为强劲，调整后EBITDA从2024年第三季度的$1.39亿上升至$1.9亿。","market":"us","thumbnail":"https://static.tigerbbs.com/fd680cd945fd32917c8ece66ec685e5f","type":0,"news_type":0,"thumbnails":["https://static.tigerbbs.com/fd680cd945fd32917c8ece66ec685e5f"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"d932a83375b5121b21ff19550e7d214b","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":true,"source_rank":0,"column":"","sentiment":"1","news_top_title":"安飞士第三季度业绩超预期，国际业务表现更为强劲","news_tag":"dataReport,movement,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CAR"],"gpt_icon":1},{"id":"2577157955","title":"再生元终止开发一款双靶点CAR-T；葛兰素史克BCMA ADC药物Blenrep获批上市","url":"https://stock-news.laohu8.com/highlight/detail?id=2577157955","media":"氨基观察","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2577157955?lang=zh_cn&edition=full","pubTime":"2025-10-24 19:55","pubTimestamp":1761306933,"startTime":"0","endTime":"0","summary":"葛兰素史克ADC药物死而复生。/ 03 /海外药闻1）再生元终止开发一款双靶点CAR-T10月23日，再生元决定放弃从2seventy bio收购的双靶点CAR-T疗法bbT369，该药物正在处于早期研究的剂量递增阶段中，用于评估治疗复发/难治性B细胞非霍奇金淋巴瘤患者。2）葛兰素史克BCMA ADC药物Blenrep获批上市10月23日，GSK宣布，美国FDA已批准其BCMA ADC药物Blenrep上市，联合硼替佐米和地塞米松，用于治疗至少接受过两种既往疗法的复发或难治性多发性骨髓瘤成年患者。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251024200649a6cc0bc6&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251024200649a6cc0bc6&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4230","BK4022","BK4532","GSK.UK","GSK","BK4588","BK4231","CAR","ADC","BK4080","LU1829250122.USD","BK4585","BK4007"],"gpt_icon":0},{"id":"2577957818","title":"【券商聚焦】建银国际：预计第三季度中国银行业利润增速将回升","url":"https://stock-news.laohu8.com/highlight/detail?id=2577957818","media":"金吾财讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2577957818?lang=zh_cn&edition=full","pubTime":"2025-10-21 08:43","pubTimestamp":1761007429,"startTime":"0","endTime":"0","summary":"金吾财讯 | 建银国际表示，MSCI中国银行指数自7月高点回调9%，但年初至今回报率仍达15%，落后全球/中国大盘约14-15个百分点。该机构认为，中国银行业是优质的补涨标的。该机构预计2025年第三季度中国银行业利润增速将回升。预测行业净利润同比增速将达2%。另预计营收与拨备前利润将小幅增长。该机构指，资产负债表质量持续改善。该机构预计，除了负债结构优化，定期存款利率下调还将进一步释放资金成本红利。","market":"sg","thumbnail":"https://static.szfiu.com/news/20250109/MWIyNWQwZjQ4NTQyNjI4OTI5NDE=.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20250109/MWIyNWQwZjQ4NTQyNjI4OTI5NDE=.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"1968144","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2449936058.SGD","03988","BK1610","IE00BQJZWZ67.USD","03968","LU1497734951.SGD","LU0516422440.USD","LU1211504680.USD","LU0211977185.USD","LU1328277881.USD","SG9999001069.SGD","BK1231","01398","LU0821914370.USD","03328","IE00BMCWC346.EUR","LU0348825331.USD","01658","IE00BZ08YT58.USD","SG9999001093.SGD","LU0640798160.USD","LU1961090484.USD","LU0106959298.USD","LU0543330566.HKD","LU1105468828.SGD","HK0000320223.HKD","LU0173614495.USD","LU0320764599.SGD","LU1282648689.USD","LU1720050803.USD","LU0819121731.USD","BK1521","LU1366334651.USD","LU0327786744.USD","LU0871576103.HKD","LU0823039010.USD","03143","CAR","LU1048484197.HKD","LU1481107354.HKD","LU1993786604.SGD","LU0370786039.SGD","LU1282649141.HKD","00939","HK0000320264.USD","LU0348827113.USD","01288","IE00B031HY20.USD","LU0051755006.USD","LU1023057109.AUD"],"gpt_icon":0},{"id":"2576085465","title":"两天4家上市药企官宣BD交易，两笔潜在最高金额超过15亿美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2576085465","media":"澎湃新闻","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2576085465?lang=zh_cn&edition=full","pubTime":"2025-10-17 14:39","pubTimestamp":1760683180,"startTime":"0","endTime":"0","summary":"两天内，已有4家国内上市药企官宣了4笔对外授权交易，涉及ADC、双抗、CAR-T疗法、等热门赛道。10月17日早间，翰森制药集团有限公司（翰森制药，3692.HK）公告称，已与罗氏就HS-20110签署许可协议，翰森制药授予罗氏在全球范围内（不含中国内地、香港、澳门和台湾）推进HS-20110开发及商业化的独家权益。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202510173537194055.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202510173537194055.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["BK1191","BK4080","BK4230","03692","CAR","BK4022","BK1589","ADC","BK4231","BK1583"],"gpt_icon":0}],"profile":{"websiteUrl":"http://avisbudgetgroup.com;ir.avisbudgetgroup.com","stockEarnings":[{"period":"1week","weight":-0.038},{"period":"1month","weight":-0.0446},{"period":"3month","weight":-0.1776},{"period":"6month","weight":-0.3616},{"period":"1year","weight":0.495},{"period":"ytd","weight":-0.0245}],"compareEarnings":[{"period":"1week","weight":0.0028},{"period":"1month","weight":0.0176},{"period":"3month","weight":0.043},{"period":"6month","weight":0.1047},{"period":"1year","weight":0.1933},{"period":"ytd","weight":0.0174}],"compareStock":{"symbol":"SPY","name":"标普500ETF"},"description":"Avis Budget Group, Inc.是一家全球领先的车辆租赁和汽车共享服务提供商，通过Avis、Budget和Zipcar运营着业内最受认可的三个品牌。该公司是北美、欧洲、澳大利亚、新西兰和某些地区领先的车辆租赁运营商。","yearOnYearQuotes":[{"month":1,"riseRate":0.5625,"avgChangeRate":0.016688},{"month":2,"riseRate":0.6,"avgChangeRate":0.044041},{"month":3,"riseRate":0.6,"avgChangeRate":0.036708},{"month":4,"riseRate":0.666667,"avgChangeRate":0.02598},{"month":5,"riseRate":0.466667,"avgChangeRate":0.01481},{"month":6,"riseRate":0.533333,"avgChangeRate":0.033428},{"month":7,"riseRate":0.6,"avgChangeRate":0.040059},{"month":8,"riseRate":0.4,"avgChangeRate":-0.00977},{"month":9,"riseRate":0.466667,"avgChangeRate":-0.027276},{"month":10,"riseRate":0.666667,"avgChangeRate":0.119671},{"month":11,"riseRate":0.666667,"avgChangeRate":0.07647},{"month":12,"riseRate":0.4,"avgChangeRate":-0.047503}],"exchange":"NASDAQ","name":"安飞士","nameEN":"Avis Budget"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.36.0","shortVersion":"4.36.0","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"安飞士(CAR)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供安飞士(CAR)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"安飞士,CAR,安飞士股票,安飞士股票老虎,安飞士股票老虎国际,安飞士行情,安飞士股票行情,安飞士股价,安飞士股市,安飞士股票价格,安飞士股票交易,安飞士股票购买,安飞士股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"安飞士(CAR)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供安飞士(CAR)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}